# OnCo record nct06830889 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06830889/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06830889", "NCT06830889" ;
  schema:name "A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy"@en ;
  schema:description "A phase 3 trial of Trastuzumab brengitecan, Trastuzumab emtansine in her2-positive breast cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06830889/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06830889> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2025-06-03" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/her2-positive-early-breast-cancer/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-brengitecan/>, <https://onco.cc/drugs/trastuzumab-emtansine/> ;
  onco:companies <https://onco.cc/companies/systimmune/> .